Search company, investor...
ContraFect company logo



Corporate Minority - P2P | IPO

Total Raised


Market Cap


Stock Price


About ContraFect

ContraFect is a biotechnology company committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms-including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza. These therapeutics will remain active regardless of future resistance to synthetic therapies, such as occurs with antibiotics. ContraFect's Mabs target conserved regions on microbes, bypassing changes in targets due to mutation. Lysins, a class of enzymes that digest the key components of bacteria, the cell wall, kill bacteria instantly upon contact, rendering bacteria incapable of developing resistance.

Headquarters Location

28 Wells Avenue

Yonkers, New York, 10701,

United States


Missing: ContraFect's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ContraFect's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ContraFect

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ContraFect is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ContraFect Patents

ContraFect has filed 38 patents.

The 3 most popular patent topics include:

  • Antibiotics
  • Bacterial diseases
  • Protein families
patents chart

Application Date

Grant Date


Related Topics




Bacteriology, Environmental soil science, Staphylococcus, Protein domains, Pathogenic bacteria


Application Date


Grant Date



Related Topics

Bacteriology, Environmental soil science, Staphylococcus, Protein domains, Pathogenic bacteria



Latest ContraFect News

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement

Feb 28, 2023

Yonkers, New York, UNITED STATES YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $4.00. Under the terms of the securities purchase agreement, ContraFect has agreed to issue 128,000 shares of common stock and pre-funded warrants to purchase 2,372,000 shares of common stock. In the concurrent private placement, which will be consummated concurrently with the offering, ContraFect also has agreed to issue warrants to purchase up to 5,000,000 shares of common stock. Each of the pre-funded warrants and the private placement warrants will be immediately exercisable, subject to a customary beneficial ownership limitation on exercisability. The private placement warrants expire five years from the date of issuance and have an exercise price of $4.00 per share of common stock. Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about March 2, 2023, subject to the satisfaction of customary closing conditions. The shares of common stock and pre-funded warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-246359) previously filed and declared effective by the Securities and Exchange Commission (SEC) on August 31, 2020. The offering of the shares of common stock and pre-funded warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. The warrants issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and/or Regulation D promulgated thereunder, have not been registered under the Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by ContraFect with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at or telephone at (212) 895-3745. Forward-Looking Statements This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding the consummation of the registered direct offering and concurrent private placement and the satisfaction of customary closing conditions with respect to the registered direct offering and concurrent private placement. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including, without limitation, that ContraFect has and expects to continue to incur significant losses, ContraFect’s need for additional funding, which may not be available, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection, changes in management may negatively affect ContraFect’s business and other important risks detailed under the caption “Risk Factors” in ContraFect's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and its other filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contacts:

ContraFect Frequently Asked Questions (FAQ)

  • Where is ContraFect's headquarters?

    ContraFect's headquarters is located at 28 Wells Avenue, Yonkers.

  • What is ContraFect's latest funding round?

    ContraFect's latest funding round is Corporate Minority - P2P.

  • How much did ContraFect raise?

    ContraFect raised a total of $38.66M.

  • Who are the investors of ContraFect?

    Investors of ContraFect include Pfizer, Equity Source Partners, Maxim Group and Cary Sucoff.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.